User talk:Ngreifer

The changes made to the page on Fluoxetine are all being done in the section entitled "History"; in this section we are adding a more detailed summary of the history of Sarafem and its use to treat PMDD. Since there is already a brief statement on Sarafem in the history summary, we are adding our edits to the section right there after the statement.

The sentence we follow with our history of Sarafem is as follows "Prozac was rebranded for the treatment of PMDD in an attempt to stem the post-patent decrease in Eli Lilly's sales of fluoxetine." This sentence itself we are editing to define what PMDD is, so instead it reads "Prozac was rebranded for the treatment of PMDD—premenstrual dysphoric disorder—in an attempt to stem the post-patent decrease in Eli Lilly's sales of fluoxetine."

Following this, there is a brief explanation of what PMDD is and its presence in the medical community. We then explain how Prozac was rebranded into Sarafem, causing the entire pharmaceutical industry to follow suit with their variations of Prozac. After this we talk about the marketing and media prescience pf Sarafem and the controversy it sparked. Such an influence caused a lot of response and in our last paragraph we explain the feminist response, as well as the significance it has on the feminist movement.

In our paragraphs we used quite a few resources in which case we will add to the body of resources. Our resources are as follows:

Paula J. Caplan (2004) The Debate About PMDD and Sarafem, Women & Therapy, 27:3-4, 55-67, DOI: 10.1300/J015v27n03_05

Caplan, Paula J. "'Premenstrual Mental Illness': The Truth About Sarafem." The Network News May 2001: 1. General OneFile. Web. 14 Mar. 2016.

Davi Johnson (2004) Selling Sarafem: Priestly and Bardic Discourses in the Construction of Premenstrual Syndrome, Women's Studies in Communication, 27:3, 330-351, DOI: 10.1080/07491409.2004.10162479

"Sarafem." Formulary July 2002: 335. Academic OneFile. Web. 14 Mar. 2016 Ngreifer (talk) 02:12, 17 March 2016 (UTC)

Response to Peer Review: The review was very helpful in pointing out our need to balance between shedding a new light on Sarafem, which, in thinking about drugs in new ways, is the point of the class, but also not going too far off topic in the social feminist history of the drug, as the wikipedia page is, after all, under the Fluoxetine page. Responding to this, we cut out a little about enlightened feminism, as the peer response suggested, and edited some other sentences to try and remain more on topic. It was also an overall reminder of our need to always write from a neutral point of view due to the sensitive nature of our topic. We also added information about medical studies conducted about Sarafem to show the medical viewpoint on the effectiveness of Sarafem. The review also pointed out our lack of a figure, which we fixed by creating a pie chart about the statistics of women with PMDD, something we think relevant to the overall Wikipedia page, not just the history section. In addition to this we created hyperlinks of concepts and words that will lead to relevant wikipedia pages. A couple of sources were added and we also got rid of the multiple references and just re-used the same reference link in the article. Since we got rid of these duplicates we added two more journal articles to total to five resources. Lastly we added a main 'History' header as well as subtitles to organize the topics that were discussed in the section.